1-cyclohexyl-3,3-dimethylbutan-1-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-cyclohexyl-3,3-dimethylbutan-1-one
• 化学式: C₁₂H₂₂O
• 分子量: 182.306
• InChiKey: YOMYTNNLDQEGDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  环己基硼酸 在 potassium fluoride 、 氯化镍二甲氧基乙烷 、 bis[3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridyl]phenyl]iridium(1+); 2-(2-pyridyl)pyridine; hexafluorophosphate 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 甲醇 、 乙二醇二甲醚 为溶剂， 反应 24.5h， 生成 1-cyclohexyl-3,3-dimethylbutan-1-one
  参考文献：
  名称：

  酰氯与仲三氟硼酸酯的增效光氧化还原/镍偶联：二烷基酮的合成。

  摘要：

  可见光光氧化还原/镍双重催化已用于酰氯与烷基三氟硼酸钾的交叉偶联。该协议基于单电子介导的烷基转移，规避了在过渡金属催化的酰化反应中使用反应性烷基金属亲核试剂的限制，并实现了一种温和而有效的合成不对称烷基酮的方法。用这种方法，已经成功地将各种酰氯与结构不同的烷基三氟硼酸钾偶联，从而以高收率产生了相应的酮。

  DOI：

  10.1021/acs.joc.6b02897

文献信息

• N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：US20160024097A1

  公开（公告）日：2016-01-28

  The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I中的N-(4-(氮杂吲唑-6-基)-苯基)-磺酰胺，其中Ar、n、X、Z、R1、R2和R3在权利要求中指定了它们的含义。式I化合物是有价值的药理活性化合物，可以调节蛋白激酶活性，特别是血清和糖皮质激素调节激酶（SGK）的活性，特别是血清和糖皮质激素调节激酶亚型1（SGK-1，SGK1）的活性，并适用于治疗SGK活性不当的疾病，例如退行性关节疾病或炎症过程，如骨关节炎或风湿病。此外，本发明还涉及制备式I化合物的方法，它们作为药物的用途以及包含它们的制剂。
• Low Calcemic, Highly Antiproliferative, Analogs of Calcitriol
  申请人：Posner Gary H.

  公开号：US20100137262A1

  公开（公告）日：2010-06-03

  The disclosure provides compounds, compositions and methods using these compounds and compositions to stimulate the differentiation of cells and inhibit excessive cell proliferation of certain cells, including cancer cells and skin cells, which may be useful in the treatment of diseases characterized by abnormal cell proliferation and/or cell differentiation such as leukemia, myelofibrosis and psoriasis without the well known effect on calcium metabolism, which gives rise to hypercalcemia.
• LOW CALCEMIC, HIGHLY ANTIPROLIFERATIVE, ANALOGS OF CALCITRIOL
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20170114013A1

  公开（公告）日：2017-04-27

  The disclosure provides compounds, compositions and methods using these compounds and compositions to stimulate the differentiation of cells and inhibit excessive cell proliferation of certain cells, including cancer cells and skin cells, which may be useful in the treatment of diseases characterized by abnormal cell proliferation and/or cell differentiation such as leukemia, myelofibrosis and psoriasis without the well known effect on calcium metabolism, which gives rise to hypercalcemia.
• US9481646B2
  申请人：——

  公开号：US9481646B2

  公开（公告）日：2016-11-01
• US9718825B2
  申请人：——

  公开号：US9718825B2

  公开（公告）日：2017-08-01